RETSAT

Across TCGA pan-cancer cohorts, RETSAT mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RETSAT data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RETSAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RETSAT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and UCEC are the cancer types where RETSAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.969	0.859	.006	28	view →
COAD	DFS	Median	All	1.000	0.887	.020	24	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.348	.003	20	view →
GBM	OS	Quartile	All	0.250	0.480	.014	11	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	4	view →
LUAD	OS	Quartile	All	0.837	0.988	.016	2	view →
PDAC	OS	Tertile	III,IV	0.535	0.244	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RETSAT–CCRCC (DFS)

Open the CCRCC breakdown →